NCT05979207: Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum |
|
|
| Completed | 1 | 18 | RoW | MMV367, P. falciparum IBSM infection | Medicines for Malaria Venture, GlaxoSmithKline, Southern Star Research Pty Ltd., ICON plc, University of the Sunshine Coast, QIMR Berghofer Medical Research Institute, Queensland Paediatric Infectious Diseases (QPID) laboratory, Swiss BioQuant A.G., Switzerland | Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome, Inflammation, Pathologic Processes, Malaria, Malaria,Falciparum, Parasitemia, Parasitic Diseases, Protozoan Infections, Antimalarials, Anti-Infective Agents | 10/23 | 10/23 | | |
NCT05979207: Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum |
|
|
| Completed | 1 | 18 | RoW | MMV367, P. falciparum IBSM infection | Medicines for Malaria Venture, GlaxoSmithKline, Southern Star Research Pty Ltd., ICON plc, University of the Sunshine Coast, QIMR Berghofer Medical Research Institute, Queensland Paediatric Infectious Diseases (QPID) laboratory, Swiss BioQuant A.G., Switzerland | Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome, Inflammation, Pathologic Processes, Malaria, Malaria,Falciparum, Parasitemia, Parasitic Diseases, Protozoan Infections, Antimalarials, Anti-Infective Agents | 10/23 | 10/23 | | |
